Publications by authors named "L Borsi"
Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets.
Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial.
Methods: ORACLE-MS included patients with a first clinical demyelinating event (FCDE or clinically isolated syndrome) who received ⩾1 course of cladribine tablets or placebo.
Recovery after moderate to severe TBI and factors influencing functional outcome: What you need to know.
J Trauma Acute Care Surg
September 2024
Traumatic brain injury (TBI) represents a major cause of death and disability, significantly impacting the lives of 2.5 million people annually in the United States. Long-term natural history studies have clarified that functional recovery continues for up to a decade, even among those who sustain severe TBI.
View Article and Find Full Text PDFArticle Synopsis
- Previous studies indicate that cladribine tablets help reduce the frequency of relapses and slow down disability progression in people with multiple sclerosis (MS).
- The CLASSIC-MS study confirmed that MS patients who took cladribine tablets maintained better mobility and experienced long-lasting benefits beyond the treatment period.
- Overall, the findings suggest that the advantages of cladribine tablets persist even after patients discontinue the medication.
Article Synopsis
- The CLASSIC-MS study focused on the long-term effectiveness of cladribine tablets in patients with relapsing multiple sclerosis.
- The analysis included 435 patients, assessing their mobility and disability status after treatment, with a primary goal of determining wheelchair use and secondary goal related to ambulatory device dependency.
- Results showed that after about 10.9 years, a high percentage of patients treated with cladribine tablets maintained good mobility and low disability levels compared to those who did not receive the treatment.
Background: Women with a BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer. This economic modeling study evaluated different preventive interventions for 30-year-old women with a confirmed BRCA (1 or 2) mutation.
Methods: A Markov model was developed to estimate the costs and benefits [i.